Bronchodilator Drugs - Southern Europe

Southern Europe

The Bronchodilator Drugs market in Southern Europe is estimated to witness a significant growth in revenue, with projections indicating that it will reach a substantial sum of US$1.19bn by the year 2024.
This growth is expected to continue at a steady pace, with an annual growth rate (CAGR 2024-2029) of 3.30%.
As a result, the market volume is anticipated to expand to US$1.40bn by 2029.
When comparing this market on a global scale, it is noteworthy that United States will contribute the highest revenue, amounting to a staggering US$17,340.00m in 2024.
In Southern Europe, the demand for bronchodilator drugs is steadily increasing due to the high prevalence of respiratory diseases in countries like Italy and Spain.

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Bronchodilator drugs are widely used in Southern Europe to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). These drugs work by relaxing the muscles around the airways, making it easier to breathe.

Customer preferences: In Southern Europe, customers prefer bronchodilator drugs that are easy to use and have minimal side effects. They also prefer drugs that provide quick relief from symptoms and are affordable.

Trends in the market: The bronchodilator drugs market in Southern Europe is expected to grow in the coming years due to the increasing prevalence of respiratory diseases and the aging population. Spain, Italy, and Portugal are the major markets in the region. The market is dominated by a few major players, but there is also a significant presence of generic drugs. The use of combination therapies is also increasing, where two or more drugs are used together to provide better relief from symptoms. In Spain, the market for bronchodilator drugs is expected to grow due to the increasing prevalence of asthma and COPD. The use of combination therapies is also increasing in the country. In Italy, the market is expected to grow due to the aging population and the increasing prevalence of respiratory diseases. The use of generic drugs is also high in the country. In Portugal, the market is expected to grow due to the increasing awareness about respiratory diseases and the availability of affordable drugs.

Local special circumstances: Southern Europe has a high prevalence of respiratory diseases due to factors such as air pollution, smoking, and allergies. The region also has a large aging population, which is more susceptible to respiratory diseases. The healthcare systems in the region are also under pressure due to budget constraints, which is leading to the increased use of generic drugs.

Underlying macroeconomic factors: The bronchodilator drugs market in Southern Europe is influenced by macroeconomic factors such as GDP growth, healthcare expenditure, and government policies. The region has been facing economic challenges in recent years, which has led to budget cuts in the healthcare sector. However, the increasing prevalence of respiratory diseases and the aging population are expected to drive the growth of the market in the coming years. Government policies such as price regulations and cost-containment measures also play a role in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.